Sees: Screening revenue of $1.848-$1.853 billion, Precision Oncology revenue of $622-$627 million, and COVID-19 testing revenue of $6 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences Announces Third-Quarter 2023 Results
- Notable companies reporting after market close
- ‘Buy the Dip’: Analysts Say These 2 Beaten-Down Stocks Offer a Compelling Entry Point — Here’s Why They Could Rebound
- Is EXAS a Buy, Before Earnings?
- Exact Sciences announces late-breaking data from pivotal BLUE-C trial